Michiel Lodder, PhD – CEOMichiel Lodder has served as Chief Executive Officer of 20Med Therapeutics since 2016. Prior to joining he was responsible for corporate and business development at Lanthio Pharma which was acquired by MorphoSys AG in 2015. Before that he was CBO at Pepscan Therapeutics and from 2006 to 2009 managing director of OctoPlus Inc, the Boston based US subsidiairy of OctoPlus NV. Michiel holds a PhD in bioorganic chemistry from the University of Virginia and a MSc from Leiden University.
Prof. Dr. Johan Engbersen - Founder and CSOJohan is Chief Scientific Officer of 20Med Therapeutics BV and em. professor of Biomedical Chemistry at the Technical Medical Centre of the University of Twente. His research during the last 15 years has focused on the development of multifunctional nanosystems for controlled drug and gene delivery. Based on an innovative class of highly effective gene delivery carriers developed in his research he founded 20Med Therapeutics in 2011 as a spin-off company of the University of Twente.
Jaap Rip, PhD - VP R&DJaap Rip is VP R&D at 20Med Therapeutics. Prior to joining 20Med, Jaap held leadership positions at Nanomi BV, Eyesiu Medicines BV and BBB Therapeutics. He is trained as a Biologist at Wageningen University and obtained a PhD at the Amsterdam Medical Center (AMC). Jaap has a specific focus on the preclinical development, scale-up and manufacturing of complex injectable formulations with a strong background in polymer and lipid based (nano)particles for sustained release and targeted drug delivery.
Tom Schwarz - ChairmanAfter obtaining a degree in Pharmacy from the Utrecht University, Tom (1954) joined Interpharm, a national Pharmaceutical wholesale company as pharmacist and marketing manager. He co-founded and was CEO of U-Gene Research, a Clinical Research Organization. In 1997 U-Gene successfully was sold to Kendle USA, which combination was listed on the Nasdaq in 2007. Tom co-founded Life Sciences Partners in Amsterdam. As general partner Tom sourced, financed and exited many life sciences companies in Europe and the USA. After 2006, Tom concentrated on financing and setting up early stage venture capital companies in the Netherlands. He co-founded the Erasmus Biomedical Fund, Life Sciences Fund Amsterdam and Twente Technology Fund. In 2017 Tom co-founded Innovation Industries.
Arnold Peterse - Board MemberArnold Peterse is since 2015 member of the board of 20Med Therapeutics. He studied synthetic organic chemistry at the state University of Utrecht whereupon he did his PhD work on the synthesis of a new group of bioactive substances. Thereafter he had several positions in the Sigma Coatings group. As general manager Research and Development of the Sigma Coatings group he was member of the Research Board of the parent company Total SA. From his research responsibility and also as business director Eastern Europe he was strongly involved in translating research results into market products. He was board member of several chemical companies in Denmark, France, UK and the Netherlands.